MX2015013197A - Biomarcadores de la respuesta farmacodinamica tumoral. - Google Patents

Biomarcadores de la respuesta farmacodinamica tumoral.

Info

Publication number
MX2015013197A
MX2015013197A MX2015013197A MX2015013197A MX2015013197A MX 2015013197 A MX2015013197 A MX 2015013197A MX 2015013197 A MX2015013197 A MX 2015013197A MX 2015013197 A MX2015013197 A MX 2015013197A MX 2015013197 A MX2015013197 A MX 2015013197A
Authority
MX
Mexico
Prior art keywords
biomarkers
pharmacodynamic response
tumor pharmacodynamic
tumor
mll1
Prior art date
Application number
MX2015013197A
Other languages
English (en)
Inventor
Christopher Wilson
Wenlai Zhou
Jinyun Chen
Yaoyu Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015013197A publication Critical patent/MX2015013197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cell Biology (AREA)

Abstract

La invención está dirigida, en parte, a los regímenes selectivos de tratamiento del cáncer basados en ensayar la presencia o ausencia de una mutación en un ácido nucleico que codifica MLL1 o la presencia de niveles reducidos de MLL1.
MX2015013197A 2013-03-15 2014-03-14 Biomarcadores de la respuesta farmacodinamica tumoral. MX2015013197A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361802327P 2013-03-15 2013-03-15
PCT/IB2014/059826 WO2014141194A2 (en) 2013-03-15 2014-03-14 Biomarker

Publications (1)

Publication Number Publication Date
MX2015013197A true MX2015013197A (es) 2016-07-07

Family

ID=50391246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013197A MX2015013197A (es) 2013-03-15 2014-03-14 Biomarcadores de la respuesta farmacodinamica tumoral.

Country Status (11)

Country Link
US (1) US20160031836A1 (es)
EP (1) EP2968349A2 (es)
JP (1) JP2016512812A (es)
KR (1) KR20150131155A (es)
CN (1) CN105050603A (es)
AU (2) AU2014229240B2 (es)
BR (1) BR112015021846A2 (es)
CA (1) CA2902699A1 (es)
MX (1) MX2015013197A (es)
RU (1) RU2015144019A (es)
WO (1) WO2014141194A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160371957A1 (en) * 2015-06-22 2016-12-22 Mc10, Inc. Method and system for structural health monitoring
RU2689400C1 (ru) * 2018-04-17 2019-05-28 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ анализа полиморфных маркеров в генах VKORC1, CYP4F2, CYP2C9, CYP2C19, ABCB1, ITGB3 для определения индивидуальной чувствительности к противосвертывающим препаратам
CN108570501B (zh) * 2018-04-28 2020-06-12 北京师范大学 多发性骨髓瘤分子分型及应用
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1611112T3 (da) * 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
US20110319415A1 (en) * 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
PL2488873T3 (pl) * 2009-10-16 2016-01-29 Novartis Ag Biomarkery odpowiedzi farmakodynamicznej wobec guza
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EA028984B1 (ru) * 2012-03-29 2018-01-31 Новартис Аг Применение (s)-пирролидин-1,2-дикарбоновой кислоты 2-амид 1-({4-метил-5-[2-(2,2,2-трифтор-1,1-диметилэтил)пиридин-4-ил]тиазол-2-ил}амида) для лечения рака

Also Published As

Publication number Publication date
WO2014141194A2 (en) 2014-09-18
EP2968349A2 (en) 2016-01-20
JP2016512812A (ja) 2016-05-09
AU2014229240B2 (en) 2017-06-15
AU2017203395A1 (en) 2017-06-08
WO2014141194A3 (en) 2015-01-08
KR20150131155A (ko) 2015-11-24
CN105050603A (zh) 2015-11-11
AU2014229240A1 (en) 2015-09-17
RU2015144019A (ru) 2017-04-24
RU2015144019A3 (es) 2018-04-03
US20160031836A1 (en) 2016-02-04
BR112015021846A2 (pt) 2017-07-18
CA2902699A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
EP3100047A4 (en) Circulating tumor cell diagnostics for prostate cancer biomarkers
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
WO2013185779A3 (en) Biomarkers for prostate cancer
PH12016500580B1 (en) Conjugated antibodies against ly75 for the treatment of cancer
HK1216779A1 (zh) 用於癌症治療的預測性生物標記物
MX2015013197A (es) Biomarcadores de la respuesta farmacodinamica tumoral.
EP3693742A3 (en) Methods of detecting prostate cancer
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
IN2014DN08970A (es)
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
MY182547A (en) Polymerase chain reaction detection system
GB201204785D0 (en) Method for determining prognosis of prostate cancer in a subject
MX2015012424A (es) Prediccion de la respuesta a los inhibidores de egfr.
EP3332037A4 (en) METHODS FOR PREDICTING PROSTATE CANCER RECHUTE
EP3498862A3 (en) Differential methylation level of cpg loci that are determinative of a biochemical reoccurrence of prostate cancer
MX2015016065A (es) Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal.
TN2014000370A1 (en) Pharmaceutical diagnostic
GB201311958D0 (en) Nucleic acid biomarkers for prostate cancer II
WO2013150167A3 (es) Micro-rna expression model as an indicator of survival of patients affected by metastatic colorectal cancer